Advertisement
Screener

Minerva Neurosciences, Inc. (NERV) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Minerva Neurosciences, Inc. Research and Development Expense

Minerva Neurosciences, Inc. (NERV) reported Research and Development Expense of $7.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07

  • Minerva Neurosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $7.19M, a 453.70% increase year-over-year.
  • Minerva Neurosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $5.25M, a 285.70% increase year-over-year.
  • Minerva Neurosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $2.17M, a 9.62% increase year-over-year.
  • Minerva Neurosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $925.38K, a 50.98% decline year-over-year.
  • Minerva Neurosciences, Inc. research and development expense for fiscal 2025 was $5.76M, a 51.60% decline from fiscal 2024.
  • Minerva Neurosciences, Inc. research and development expense for fiscal 2024 was $11.90M, a 6.35% decline from fiscal 2023.
  • Minerva Neurosciences, Inc. research and development expense for fiscal 2023 was $12.71M, a 13.27% decline from fiscal 2022.
  • Minerva Neurosciences, Inc. research and development expense for fiscal 2022 was $14.65M, a 54.28% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$7.19M
10-Q · filed 2026-08-07
$12.44M
10-Q · filed 2026-08-07
$14.62M
derived: sum of 3 quarters · filed 2026-08-07
$15.54M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31$5.25M
10-Q · filed 2026-05-05
$7.43M
derived: sum of 2 quarters · filed 2026-05-05
$8.35M
derived: sum of 3 quarters · filed 2026-05-05
$9.65M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31$2.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
$3.10M
derived: sum of 2 quarters · filed 2026-03-11
$4.40M
derived: sum of 3 quarters · filed 2026-08-07
$5.76M
10-K · filed 2026-03-11
2025-09-30$925.38K
10-Q · filed 2025-11-05
$2.22M
derived: sum of 2 quarters · filed 2026-08-07
$3.59M
10-Q · filed 2025-11-05
$5.57M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30$1.30M
10-Q · filed 2026-08-07
$2.66M
10-Q · filed 2026-08-07
$4.64M
derived: sum of 3 quarters · filed 2026-08-07
$6.53M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31$1.36M
10-Q · filed 2026-05-05
$3.35M
derived: sum of 2 quarters · filed 2026-05-05
$5.23M
derived: sum of 3 quarters · filed 2026-05-05
$9.09M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$1.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
$3.87M
derived: sum of 2 quarters · filed 2026-03-11
$7.73M
derived: sum of 3 quarters · filed 2026-03-11
$11.90M
10-K · filed 2026-03-11
2024-09-30$1.89M
10-Q · filed 2025-11-05
$5.75M
derived: sum of 2 quarters · filed 2025-11-05
$9.92M
10-Q · filed 2025-11-05
$14.64M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$3.86M
10-Q · filed 2025-08-14
$8.03M
10-Q · filed 2025-08-14
$12.75M
derived: sum of 3 quarters · filed 2025-08-14
$16.19M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$4.17M
10-Q · filed 2025-05-13
$8.89M
derived: sum of 2 quarters · filed 2025-05-13
$12.33M
derived: sum of 3 quarters · filed 2025-05-13
$14.22M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$4.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$8.16M
derived: sum of 2 quarters · filed 2025-02-25
$10.05M
derived: sum of 3 quarters · filed 2025-02-25
$12.71M
10-K · filed 2025-02-25
2023-09-30$3.44M
10-Q · filed 2024-11-05
$5.33M
derived: sum of 2 quarters · filed 2024-11-05
$7.98M
10-Q · filed 2024-11-05
$11.17M
derived: sum of 4 quarters · filed 2024-11-05
2023-06-30$1.89M
10-Q · filed 2024-08-06
$4.54M
10-Q · filed 2024-08-06
$7.73M
derived: sum of 3 quarters · filed 2024-08-06
$10.10M
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$2.65M
10-Q · filed 2024-05-01
$5.84M
derived: sum of 2 quarters · filed 2024-05-01
$8.21M
derived: sum of 3 quarters · filed 2024-05-01
$12.34M
derived: sum of 4 quarters · filed 2024-05-01
2022-12-31$3.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22
$5.56M
derived: sum of 2 quarters · filed 2024-02-22
$9.69M
derived: sum of 3 quarters · filed 2024-02-22
$14.65M
10-K · filed 2024-02-22
2022-09-30$2.37M
10-Q · filed 2023-11-07
$6.50M
derived: sum of 2 quarters · filed 2023-11-07
$11.46M
10-Q · filed 2023-11-07
$30.21M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$4.13M
10-Q · filed 2023-08-01
$9.09M
10-Q · filed 2023-08-01
$27.84M
derived: sum of 3 quarters · filed 2023-08-01
$32.35M
derived: sum of 4 quarters · filed 2023-08-01
2022-03-31$4.96M
10-Q · filed 2023-05-15
$23.71M
derived: sum of 2 quarters · filed 2023-05-15
$28.22M
derived: sum of 3 quarters · filed 2023-05-15
$33.74M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$18.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08
$23.26M
derived: sum of 2 quarters · filed 2023-03-08
$28.78M
derived: sum of 3 quarters · filed 2023-03-08
$32.04M
10-K · filed 2023-03-08
2021-09-30$4.51M
10-Q · filed 2022-11-09
$10.03M
derived: sum of 2 quarters · filed 2022-11-09
$13.29M
10-Q · filed 2022-11-09
$16.84M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$5.52M
10-Q · filed 2022-08-09
$8.78M
10-Q · filed 2022-08-09
$12.33M
derived: sum of 3 quarters · filed 2022-08-09
$16.97M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$3.26M
10-Q · filed 2022-05-04
$6.81M
derived: sum of 2 quarters · filed 2022-05-04
$11.45M
derived: sum of 3 quarters · filed 2022-05-04
$17.22M
derived: sum of 4 quarters · filed 2022-05-04
2020-12-31$3.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$8.19M
derived: sum of 2 quarters · filed 2022-03-01
$13.96M
derived: sum of 3 quarters · filed 2022-03-01
$22.04M
10-K · filed 2022-03-01
2020-09-30$4.64M
10-Q · filed 2021-11-08
$10.41M
derived: sum of 2 quarters · filed 2021-11-08
$18.49M
10-Q · filed 2021-11-08
$47.01M
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30$5.77M
10-Q · filed 2021-08-02
$13.85M
10-Q · filed 2021-08-02
$42.37M
derived: sum of 3 quarters · filed 2021-08-02
$52.05M
derived: sum of 4 quarters · filed 2021-08-02
2020-03-31$8.08M
10-Q · filed 2021-05-12
$36.61M
derived: sum of 2 quarters · filed 2021-05-12
$46.28M
derived: sum of 3 quarters · filed 2021-05-12
$54.60M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31$28.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08
$38.20M
derived: sum of 2 quarters · filed 2021-03-08
$46.52M
derived: sum of 3 quarters · filed 2021-03-08
$58.12M
10-K · filed 2021-03-08
2019-09-30$9.67M
10-Q · filed 2020-11-02
$17.99M
derived: sum of 2 quarters · filed 2020-11-02
$29.60M
10-Q · filed 2020-11-02
$38.61M
derived: sum of 4 quarters · filed 2020-11-02
2019-06-30$8.32M
10-Q · filed 2020-08-03
$19.93M
10-Q · filed 2020-08-03
$28.93M
derived: sum of 3 quarters · filed 2020-08-03
$37.30M
derived: sum of 4 quarters · filed 2020-08-03
2019-03-31$11.61M
10-Q · filed 2020-05-04
$20.61M
derived: sum of 2 quarters · filed 2020-05-04
$28.98M
derived: sum of 3 quarters · filed 2020-05-04
$38.05M
derived: sum of 4 quarters · filed 2020-05-04
2018-12-31$9.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09
$17.38M
derived: sum of 2 quarters · filed 2020-03-09
$26.44M
derived: sum of 3 quarters · filed 2020-03-09
$34.89M
10-K · filed 2020-03-09
2018-09-30$8.37M
10-Q · filed 2019-11-04
$17.43M
derived: sum of 2 quarters · filed 2019-11-04
$25.88M
10-Q · filed 2019-11-04
$32.42M
derived: sum of 4 quarters · filed 2019-11-04
2018-06-30$9.06M
10-Q · filed 2019-08-05
$17.51M
10-Q · filed 2019-08-05
$24.05M
derived: sum of 3 quarters · filed 2019-08-05
$33.01M
derived: sum of 4 quarters · filed 2019-08-05
2018-03-31$8.45M
10-Q · filed 2019-05-06
$14.99M
derived: sum of 2 quarters · filed 2019-05-06
$23.95M
derived: sum of 3 quarters · filed 2019-05-06
$31.09M
derived: sum of 4 quarters · filed 2019-05-06
2017-12-31$6.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
$15.50M
derived: sum of 2 quarters · filed 2019-03-12
$22.64M
derived: sum of 3 quarters · filed 2019-03-12
$30.26M
10-K · filed 2019-03-12
2017-09-30$8.96M
10-Q · filed 2018-11-05
$16.10M
derived: sum of 2 quarters · filed 2018-11-05
$23.71M
10-Q · filed 2018-11-05
$30.21M
derived: sum of 4 quarters · filed 2018-11-05
2017-06-30$7.14M
10-Q · filed 2018-08-02
$14.76M
10-Q · filed 2018-08-02
$21.26M
derived: sum of 3 quarters · filed 2018-08-02
$27.11M
derived: sum of 4 quarters · filed 2018-08-02
2017-03-31$7.61M
10-Q · filed 2018-05-03
$14.11M
derived: sum of 2 quarters · filed 2018-05-03
$19.97M
derived: sum of 3 quarters · filed 2018-05-03
$22.68M
derived: sum of 4 quarters · filed 2018-05-03
2016-12-31$6.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$12.35M
derived: sum of 2 quarters · filed 2018-03-12
$15.07M
derived: sum of 3 quarters · filed 2018-03-12
$20.44M
10-K · filed 2018-03-12
2016-09-30$5.85M
10-Q · filed 2017-11-06
$8.57M
derived: sum of 2 quarters · filed 2017-11-06
$13.94M
10-Q · filed 2017-11-06
$20.20M
derived: sum of 4 quarters · filed 2018-03-12
2016-06-30$2.71M
10-Q · filed 2017-08-03
$8.09M
10-Q · filed 2017-08-03
$14.35M
derived: sum of 3 quarters · filed 2018-03-12
$18.18M
derived: sum of 4 quarters · filed 2018-03-12
2016-03-31$5.37M
10-Q · filed 2017-05-04
$11.63M
derived: sum of 2 quarters · filed 2018-03-12
$15.46M
derived: sum of 3 quarters · filed 2018-03-12
$19.95M
derived: sum of 4 quarters · filed 2018-03-12
2015-12-31$6.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$10.09M
derived: sum of 2 quarters · filed 2018-03-12
$14.57M
derived: sum of 3 quarters · filed 2018-03-12
$18.53M
10-K · filed 2018-03-12
2015-09-30$3.83M
10-Q · filed 2016-11-03
$8.31M
derived: sum of 2 quarters · filed 2016-11-03
$12.27M
10-Q · filed 2016-11-03
$15.24M
derived: sum of 4 quarters · filed 2017-03-13
2015-06-30$4.48M
10-Q · filed 2016-08-04
$8.45M
10-Q · filed 2016-08-04
$11.41M
derived: sum of 3 quarters · filed 2017-03-13
$36.15M
derived: sum of 4 quarters · filed 2017-03-13
2015-03-31$3.96M
10-Q · filed 2016-05-03
$6.93M
derived: sum of 2 quarters · filed 2017-03-13
$31.67M
derived: sum of 3 quarters · filed 2017-03-13
$46.22M
derived: sum of 4 quarters · filed 2017-03-13
2014-12-31$2.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13
$27.71M
derived: sum of 2 quarters · filed 2017-03-13
$42.26M
derived: sum of 3 quarters · filed 2017-03-13
$42.91M
10-K · filed 2017-03-13
2014-09-30$24.74M
10-Q · filed 2015-11-05
$39.29M
derived: sum of 2 quarters · filed 2015-11-05
$39.94M
10-Q · filed 2015-11-05
$40.04M
derived: sum of 4 quarters · filed 2015-11-05
2014-06-30$14.55M
10-Q · filed 2015-08-05
$15.14M
10-Q · filed 2015-08-05
$15.30M
derived: sum of 3 quarters · filed 2015-08-05
$15.50M
derived: sum of 4 quarters · filed 2015-08-05
2014-03-31$585.94K
10-Q · filed 2015-05-07
$749.98K
derived: sum of 2 quarters · filed 2015-05-07
$940.64K
derived: sum of 3 quarters · filed 2015-05-07
$1.19M
derived: sum of 4 quarters · filed 2015-05-07
2013-12-31$164.04K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26
$354.71K
derived: sum of 2 quarters · filed 2015-03-26
$604.55K
derived: sum of 3 quarters · filed 2015-03-26
$708.49K
10-K · filed 2015-03-26
2013-09-30$190.66K
10-Q · filed 2014-11-06
$440.51K
derived: sum of 2 quarters · filed 2014-11-06
$544.45K
10-Q · filed 2014-11-06
2013-06-30$249.84K
10-Q · filed 2014-08-07
$353.78K
10-Q · filed 2014-08-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Annexon, Inc. (ANNX)United States$0.147B-4.22
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91